|
KMID : 1143120220120030027
|
|
Asia Pacific Allergy
2022 Volume.12 No. 3 p.27 ~ p.27
|
|
|
Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein
|
|
Triwatcharikorn Jidapa
Klaewsongkram Jettanong
Rerknimitr Pawinee
|
|
|
Abstract
|
|
|
|
Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein. This reaction emphasized that delayed urticaria may not be an allergic reaction to excipient but rather to the immunogen as such as SARS-CoV-2 spike protein.
|
|
|
KEYWORD
|
|
|
Delayed urticaria, COVID-19 vaccination, BNT162 vaccine, Pfizer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|